UK hypertension care up for review:
This article was originally published in Clinica
Executive Summary
The UK's National Institute for Health and Clinical Excellence (NICE) is preparing to undertake a review of its guidelines on the management of hypertension. The current guidelines, issued in August 2004, included a rejection of automated ambulatory blood pressure monitoring or home monitoring devices for routine use, on the basis that "their value has not been adequately established". Current policy also emphasises the need to consider assessing cardiovascular risk, covering testing for diabetes, hypertensive damage to the heart and kidneys and secondary causes of hypertension. A preliminary review of new data will be conducted in collaboration with the British Hypertension Society, given that it too will take into account the recently-concluded Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) as part of the development of its own guidelines.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.